JACC
HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
 QUICK SEARCH:   [advanced]


     


J Am Coll Cardiol, 2007; 50:1054-1060, doi:10.1016/j.jacc.2007.04.091 (Published online 23 August 2007).
© 2007 by the American College of Cardiology Foundation
This Article
Right arrow Abstract Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (8)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kempf, T.
Right arrow Articles by Wollert, K. C.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Kempf, T.
Right arrow Articles by Wollert, K. C.
Related Collections
Right arrowRelated Article

Prognostic Utility of Growth Differentiation Factor-15 in Patients With Chronic Heart Failure

Tibor Kempf, MD*,1, Stephan von Haehling, MD{dagger},{ddagger}, Timo Peter, MS*, Tim Allhoff, MS*, Mariantonietta Cicoira, MD, PhD§, Wolfram Doehner, MD, PhD{dagger}, Piotr Ponikowski, MD||, Gerasimos S. Filippatos, MD#, Piotr Rozentryt, MD**, Helmut Drexler, MD*,1, Stefan D. Anker, MD, PhD{dagger},{ddagger} and Kai C. Wollert, MD*,1,*

* Department of Cardiology and Angiology, Hannover Medical School, Hannover, Germany
{dagger} Division of Applied Cachexia Research, Department of Cardiology, Charité, Berlin, Germany
{ddagger} Department of Clinical Cardiology, National Heart and Lung Institute, Imperial College School of Medicine, London, United Kingdom
§ Section of Cardiology, University of Verona, Verona, Italy
|| Department of Cardiology, Military Hospital, Wroclaw, Poland
# Department of Cardiology, University Hospital, Athens, Greece
** Department of Cardiology, Silesian Center for Heart Disease, Zabrze, Poland.


Figure 1
View larger version (8K):
[in this window]
[in a new window]
[Download PPT slide]
 
Figure 1 GDF-15 Levels in 455 Patients With Chronic Heart Failure Stratified According to NYHA Functional Class or NT-proBNP Levels at Study Entry

Patients were stratified according to New York Heart Association (NYHA) functional class (A) or NT-proBNP quartiles (B). The GDF-15 levels are presented as box (25th percentile, median, 75th percentile) and whisker (10th and 90th percentiles) plots. Patient numbers are indicated. The NT-proBNP levels in the first quartile ranged from 20 to 305 ng/l, in the second quartile from 306 to 800 ng/l, in the third quartile from 801 to 2,307 ng/l, and in the fourth quartile from 2,308 to 88,300 ng/l. p < 0.001 by Kruskal-Wallis test in both panels. GDF-15 = growth differentiation factor 15; NT-proBNP = amino-terminal pro–B-type natriuretic peptide.

 

Figure 2
View larger version (15K):
[in this window]
[in a new window]
[Download PPT slide]
 
Figure 2 Cumulative Survival in 455 Patients With CHF According to Quartiles of GDF-15 at Study Entry

The number of patients at risk and mortality rates are shown below the graph. p < 0.001 by simple Cox regression analysis. GDF = growth differentiation factor.

 

Figure 3
View larger version (24K):
[in this window]
[in a new window]
[Download PPT slide]
 
Figure 3 Risk of Death During Follow-Up Associated With a GDF-15 Level >2,729 ng/l at Study Entry

Patient numbers are shown in parentheses. For analyses according to age, body mass index (BMI), creatinine, and creatinine clearance (Crea Cl), median values of the study population were used to create subgroups of comparable size. Patients were also stratified according to presence or absence of anemia (hemoglobin ≤13 g/dl in men, ≤12 g/dl in women), hyperuricemia (uric acid >400 µmol/l), angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) therapy, and beta-blocker therapy at study entry. The hazard ratio (HR) could not be calculated in patients not receiving ACEI/ARB therapy (there were 0 deaths in 12 patients with growth differentiation factor (GDF)-15 levels ≤2,729 ng/l, and 8 deaths in 21 patients with GDF-15 levels >2,729 ng/l). The p values were obtained by simple Cox regression analysis. CI = confidence interval.

 

Figure 4
View larger version (8K):
[in this window]
[in a new window]
[Download PPT slide]
 
Figure 4 One-Year Mortality Rates According to NYHA Functional Class, LVEF, NT-proBNP, and Levels of GDF-15

The number of deaths per number of patients is shown above each bar. For analyses according to LVEF and NT-proBNP, the median values of the study population were used to create subgroups of comparable size. The p values were obtained by simple Cox regression analysis. LVEF = left ventricular ejection fraction; other abbreviations as in Figures 1 and 3.

 





HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
Copyright © 2007 by the American College of Cardiology Foundation.